Crossmark

Qualitative research with patients and caregivers of patients with PIK3CA related overgrowth spectrum: content validity of clinical outcome assessments

Crossref DOI link: https://doi.org/10.1186/s41687-022-00481-8

Published Online: 2022-07-13

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Raymond, Kimberly https://orcid.org/0000-0001-9096-9269
Vallow, Susan

Saucier, Cory

Jackson, Kristi

White, Michelle K.

Lovley, Andrew

D’Alessio, Denise
License Information

Text and Data Mining valid from 2022-07-13

Version of Record valid from 2022-07-13
More Information

Article History

Received: 28 October 2021

Accepted: 9 June 2022

First Online: 13 July 2022

Declarations

:

: Full Institutional Review Board (IRB) approval was obtained from WCG IRB (USA) prior to recruitment and written informed consent was obtained prior to patient interviews with consent confirmed verbally at the start of each interview; all interview guides, including revisions, were approved by the IRB prior to their use.

: Not applicable.

: SV and DD are employees of Novartis and stockholders of Novartis Pharmaceuticals. KR, MW, KJ, CS, and AL are all employees of QM and have no conflicts of interest to declare.

Document is current

Any future updates will be listed below